Articles with public access mandates - Karen SheppardLearn more
Not available anywhere: 3
AKT promotes rRNA synthesis and cooperates with c-MYC to stimulate ribosome biogenesis in cancer
JC Chan, KM Hannan, K Riddell, PY Ng, A Peck, RS Lee, S Hung, ...
Science signaling 4 (188), ra56-ra56, 2011
Mandates: Swiss National Science Foundation
Enhanced GAB2 Expression Is Associated with Improved Survival in High-Grade Serous Ovarian Cancer and Sensitivity to PI3K Inhibition
SJ Davis, KE Sheppard, MS Anglesio, J George, N Traficante, S Fereday, ...
Molecular cancer therapeutics 14 (6), 1495-1503, 2015
Mandates: National Health and Medical Research Council, Australia, Canadian Institutes …
Inhibition of the MNK1/2–eIF4E Axis Augments Palbociclib-Mediated Antitumor Activity in Melanoma and Breast Cancer
SA Prabhu, O Moussa, C Gonçalves, JH LaPierre, H Chou, F Huang, ...
Molecular Cancer Therapeutics 22 (2), 192-204, 2023
Mandates: Canadian Institutes of Health Research, Fonds de recherche du Québec - Santé …
Available somewhere: 34
The cell-cycle regulator CDK4: an emerging therapeutic target in melanoma
KE Sheppard, GA McArthur
Clinical Cancer Research 19 (19), 5320-5328, 2013
Mandates: National Health and Medical Research Council, Australia
Response of BRAF-Mutant Melanoma to BRAF Inhibition Is Mediated by a Network of Transcriptional Regulators of Glycolysis
TJ Parmenter, M Kleinschmidt, KM Kinross, ST Bond, J Li, MR Kaadige, ...
Cancer discovery 4 (4), 423-433, 2014
Mandates: US National Institutes of Health, National Health and Medical Research …
An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice
KM Kinross, KG Montgomery, M Kleinschmidt, P Waring, I Ivetac, A Tikoo, ...
The Journal of clinical investigation 122 (2), 553-557, 2012
Mandates: Swiss National Science Foundation
Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell …
RJ Young, K Waldeck, C Martin, JH Foo, DP Cameron, L Kirby, H Do, ...
Pigment cell & melanoma research 27 (4), 590-600, 2014
Mandates: National Health and Medical Research Council, Australia
First-in-human RNA polymerase I transcription inhibitor CX-5461 in patients with advanced hematologic cancers: results of a phase I dose-escalation study
A Khot, N Brajanovski, DP Cameron, N Hein, KH Maclachlan, E Sanij, ...
Cancer discovery 9 (8), 1036-1049, 2019
Mandates: National Health and Medical Research Council, Australia
The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma
R Ramsdale, RN Jorissen, FZ Li, S Al-Obaidi, T Ward, KE Sheppard, ...
Science signaling 8 (390), ra82-ra82, 2015
Mandates: National Health and Medical Research Council, Australia
CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer
E Sanij, KM Hannan, J Xuan, S Yan, JE Ahern, AS Trigos, N Brajanovski, ...
Nature communications 11 (1), 2641, 2020
Mandates: National Health and Medical Research Council, Australia
LRP1B deletion in high-grade serous ovarian cancers is associated with acquired chemotherapy resistance to liposomal doxorubicin
PA Cowin, J George, S Fereday, E Loehrer, P Van Loo, C Cullinane, ...
Cancer research 72 (16), 4060-4073, 2012
Mandates: National Health and Medical Research Council, Australia, Research Foundation …
Inhibition of RNA polymerase I transcription initiation by CX-5461 activates non-canonical ATM/ATR signaling
J Quin, KT Chan, JR Devlin, DP Cameron, J Diesch, C Cullinane, J Ahern, ...
Oncotarget 7 (31), 49800, 2016
Mandates: National Health and Medical Research Council, Australia
Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors
KE Sheppard, C Cullinane, KM Hannan, M Wall, J Chan, F Barber, J Foo, ...
European journal of cancer 49 (18), 3936-3944, 2013
Mandates: National Health and Medical Research Council, Australia
Regulation of PRMT5–MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma
S AbuHammad, C Cullinane, C Martin, Z Bacolas, T Ward, H Chen, ...
Proceedings of the National Academy of Sciences 116 (36), 17990-18000, 2019
Mandates: US National Institutes of Health, National Health and Medical Research …
Functional analysis of genes in regions commonly amplified in high-grade serous and endometrioid ovarian cancer
SJ Davis, KE Sheppard, RB Pearson, IG Campbell, KL Gorringe, ...
Clinical cancer research 19 (6), 1411-1421, 2013
Mandates: National Health and Medical Research Council, Australia
Palbociclib synergizes with BRAF and MEK inhibitors in treatment naïve melanoma but not after the development of BRAF inhibitor resistance
CA Martin, C Cullinane, L Kirby, S Abuhammad, EJ Lelliott, K Waldeck, ...
International Journal of Cancer 142 (10), 2139-2152, 2018
Mandates: National Health and Medical Research Council, Australia
Whole exome sequencing identifies a recurrent RQCD1 P131L mutation in cutaneous melanoma
SQ Wong, A Behren, VJ Mar, K Woods, J Li, C Martin, KE Sheppard, ...
Oncotarget 6 (2), 1115, 2015
Mandates: National Health and Medical Research Council, Australia
Desmoglein 2 promotes vasculogenic mimicry in melanoma and is associated with poor clinical outcome
LY Tan, C Mintoff, MZ Johan, BW Ebert, C Fedele, YF Zhang, P Szeto, ...
Oncotarget 7 (29), 46492, 2016
Mandates: National Health and Medical Research Council, Australia
Obesity and the impact on cutaneous melanoma: Friend or foe?
LK Smith, S Arabi, EJ Lelliott, GA McArthur, KE Sheppard
Cancers 12 (6), 1583, 2020
Mandates: National Health and Medical Research Council, Australia
Immunomodulatory effects of BRAF, MEK, and CDK4/6 inhibitors: implications for combining targeted therapy and immune checkpoint blockade for the treatment of melanoma
EJ Lelliott, GA McArthur, J Oliaro, KE Sheppard
Frontiers in Immunology 12, 661737, 2021
Mandates: National Health and Medical Research Council, Australia
Publication and funding information is determined automatically by a computer program